Phio Pharmaceuticals Corp (PHIO)

$1.19 -0.06 (-4.80%)
Market Cap 7.16M
Revenue (ttm) 0.00
Net Income (ttm) -7.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 464,200
Avg Vol 3,557,704
Day's Range N/A - N/A
Shares Out 5.73M
Stochastic %K 2%
Beta 0.96
Analysts Sell
Price Target $14.00

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology
Sector: Healthcare
Phone: 508 767 3861
Address:
11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States
Bigmoney47
Bigmoney47 Nov. 21 at 10:20 AM
$PHIO 9%📈 pre-market, What's wrong with the company? Will it close soon .
0 · Reply
JEB6
JEB6 Nov. 20 at 11:01 PM
$PHIO
0 · Reply
PitaPierogi
PitaPierogi Nov. 20 at 10:27 PM
$PHIO Warrant shares DO NOT EXIST in the market unless the holders exercise them by paying $2.05/share. Since PHIO is trading at $1.19, exercising warrants right now would be: Paying $2.05 For stock worth $1.19 → They would lose money. So no exercises happen and no new shares hit the float at this price.
0 · Reply
ckruel
ckruel Nov. 20 at 9:44 PM
$PHIO files to sell 11.76 million shares to holders…..
0 · Reply
Stripette
Stripette Nov. 20 at 9:37 PM
$PHIO why is it going up?
0 · Reply
PitaPierogi
PitaPierogi Nov. 20 at 8:32 PM
$PHIO algos hard at work. Soon they'll turn to buy and we'll see 4's 5's
0 · Reply
Treechain
Treechain Nov. 20 at 6:10 PM
$PHIO news of partnership is imminent . They already have production pipeline in place. but they will have some interested parties wanting to take this to other forms of cancer. HOLD for the gold
1 · Reply
ckruel
ckruel Nov. 20 at 2:15 PM
$PHIO H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Phio Pharmaceuticals today and set a price target of $14.00
0 · Reply
PitaPierogi
PitaPierogi Nov. 19 at 10:25 PM
$PHIO lmao
0 · Reply
Roaring_Capybara
Roaring_Capybara Nov. 19 at 10:25 PM
$PHIO What the Phuk happened. Did they flip the massive 5k share purchase ..... 🤣
0 · Reply
Latest News on PHIO
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 17, 2025, 8:45 AM EST - 3 days ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:15 PM EST - 7 days ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 10:30 AM EST - 13 days ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 7, 2025, 7:45 AM EST - 13 days ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 1:40 PM EST - 17 days ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Nov 3, 2025, 7:45 AM EST - 17 days ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 31, 2025, 10:15 AM EDT - 20 days ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Oct 21, 2025, 7:45 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 18, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:15 PM EDT - 3 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 3:04 PM EDT - 4 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 12:36 PM EDT - 4 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jul 25, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 25, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 24, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Jun 6, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:15 PM EDT - 6 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 9, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Apr 3, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 4:00 PM EDT - 8 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 10, 2025, 7:45 AM EDT - 9 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Feb 20, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 22, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 4:15 PM EST - 10 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 11 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 12:45 PM EST - 11 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 13, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Jan 2, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 1:15 PM EST - 11 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Bigmoney47
Bigmoney47 Nov. 21 at 10:20 AM
$PHIO 9%📈 pre-market, What's wrong with the company? Will it close soon .
0 · Reply
JEB6
JEB6 Nov. 20 at 11:01 PM
$PHIO
0 · Reply
PitaPierogi
PitaPierogi Nov. 20 at 10:27 PM
$PHIO Warrant shares DO NOT EXIST in the market unless the holders exercise them by paying $2.05/share. Since PHIO is trading at $1.19, exercising warrants right now would be: Paying $2.05 For stock worth $1.19 → They would lose money. So no exercises happen and no new shares hit the float at this price.
0 · Reply
ckruel
ckruel Nov. 20 at 9:44 PM
$PHIO files to sell 11.76 million shares to holders…..
0 · Reply
Stripette
Stripette Nov. 20 at 9:37 PM
$PHIO why is it going up?
0 · Reply
PitaPierogi
PitaPierogi Nov. 20 at 8:32 PM
$PHIO algos hard at work. Soon they'll turn to buy and we'll see 4's 5's
0 · Reply
Treechain
Treechain Nov. 20 at 6:10 PM
$PHIO news of partnership is imminent . They already have production pipeline in place. but they will have some interested parties wanting to take this to other forms of cancer. HOLD for the gold
1 · Reply
ckruel
ckruel Nov. 20 at 2:15 PM
$PHIO H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Phio Pharmaceuticals today and set a price target of $14.00
0 · Reply
PitaPierogi
PitaPierogi Nov. 19 at 10:25 PM
$PHIO lmao
0 · Reply
Roaring_Capybara
Roaring_Capybara Nov. 19 at 10:25 PM
$PHIO What the Phuk happened. Did they flip the massive 5k share purchase ..... 🤣
0 · Reply
newbulloh2
newbulloh2 Nov. 19 at 9:56 PM
$PHIO yess!!! We have buyers!!!!!!!!!!!!!
0 · Reply
DERDER
DERDER Nov. 19 at 8:55 PM
$PHIO Lots of huge purchases over the last week.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Nov. 19 at 7:50 PM
$PHIO CEO purchased 5,000 shares at $1.27 for a total of $6,350. Bitterman Robert J now owns 276,421 shares. https://ceo-buys.com
0 · Reply
Treechain
Treechain Nov. 19 at 6:54 PM
$PHIO well that was a fake head nod as it continues down the staircase lol
0 · Reply
Treechain
Treechain Nov. 19 at 6:08 PM
$PHIO somebody just bought 80,000 shares in 60 seconds
0 · Reply
Treechain
Treechain Nov. 19 at 6:06 PM
$PHIO somebody just bought a chunk hard
0 · Reply
Treechain
Treechain Nov. 19 at 5:15 PM
$PHIO volume down to dust particles floating around. The wait for next PR may be excrusiating.
0 · Reply
DERDER
DERDER Nov. 19 at 3:49 PM
$PHIO Just like PHIO in the near term, will be smokin…
0 · Reply
PitaPierogi
PitaPierogi Nov. 19 at 3:34 PM
$PHIO
0 · Reply
DosGatos
DosGatos Nov. 19 at 3:28 PM
$PHIO Phio’s other “pipelines”:
0 · Reply
PitaPierogi
PitaPierogi Nov. 19 at 3:08 PM
$PHIO PHIO’s Other Pipelines: PH-894: Preclinical results show it helps the immune system recognize tumors better. Activates T cells effectively, making it a strong immunotherapy candidate. PH-804: Targets TIGIT to boost natural killer cell activity in preclinical models. Shows promise in enhancing immune response against tumors. Timeline and Funding: They’re aiming to move these into clinical trials possibly next year. Recent warrant funding should support these next steps, giving them a solid cash runway.
0 · Reply
Bigmoney47
Bigmoney47 Nov. 19 at 2:37 PM
$PHIO today 1$ or 1.50 still hold
0 · Reply